An observational study of antiretroviral drug resistance in treatment-naïve patients with HIV infection in New Zealand, from 2007 to 2011
Mark Hobbs A D , Jinyang Shi B , Michael Maze C and Simon Briggs CA Department of Medicine, Middlemore Hospital, Private Bag 93311, Otahuhu, Auckland 1640, New Zealand.
B Virology Laboratory, LabPLUS, Auckland City Hospital, Private Bag 92024, Auckland Mail Centre, Auckland 1142, New Zealand.
C Infectious Disease Unit, Auckland City Hospital, Private Bag 92024, Auckland Mail Centre, Auckland 1142, New Zealand.
D Corresponding author. Email: mrhobbsie@hotmail.com
Sexual Health 12(6) 556-559 https://doi.org/10.1071/SH14226
Submitted: 26 November 2014 Accepted: 7 July 2015 Published: 17 August 2015
Abstract
Background: Genotypic testing for antiretroviral drug resistance is recommended for all patients newly diagnosed with HIV infection. This study sought to quantify the prevalence of antiretroviral drug resistance in treatment-naïve patients with HIV infection in New Zealand. Methods: All genotypic antiretroviral drug resistance testing in New Zealand is performed at LabPLUS, Auckland City Hospital. The clinicians who requested antiretroviral drug resistance testing during the period 2007–2011 were contacted and were asked to identify which patients with HIV infection were treatment-naïve at the time of testing. Results of the antiretroviral drug resistance tests for treatment-naïve patients with HIV infection were reviewed and the prevalence of resistance determined. Results: Two hundred and 10 treatment-naïve patients with HIV infection who had antiretroviral drug resistance testing performed were included; 20 (10%) were found to have a significant resistance mutation. Nine patients had virus resistant to one or more nucleoside reverse transcriptase inhibitors, 13 to non-nucleoside reverse transcriptase inhibitors and one to protease inhibitors. Conclusions: The prevalence of antiretroviral drug resistance in treatment-naïve patients with HIV infection identified in this study is comparable to rates identified in studies from North America, the UK and Europe. This prevalence demonstrates the need for antiretroviral drug resistance testing for all treatment-naïve patients with HIV infection in New Zealand.
Additional keywords: antiretroviral drugs, antiretroviral resistance mutations, HIV resistance testing, transmitted HIV drug resistance.
References
[1] Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P, Mackie N, Muir D, Murphy G, Orkin C, Post F, Rooney G, Sabin C, Sherr L, Smit E, Tong W, Ustianowski A, Valappil M, Walsh J, Williams M, Yirrell D. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012; 13 1–44.| British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC38%2FnslCnsw%3D%3D&md5=933e27796dd08ab5bdc86a4881389e91CAS | 22171742PubMed |
[2] Vandamme A-M, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit J-C, Soriano V, Walter H, Sonnerborg A. European guidelines for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13 77–108.
| 21587341PubMed |
[3] Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available online at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [verified 15 August 2013].
[4] The Australasian Society for HIV Medicine. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. With Australian Commentary. Available online at: http://arv.ashm.org.au/ [verified 15 August 2013].
[5] Hirsch MS, Günthard HF, Schapiro JM, Brun Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillary D, Yeni PG, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008; 47 266–85.
| Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel.Crossref | GoogleScholarGoogle Scholar | 18549313PubMed |
[6] Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldi SJ, Sadownik SN, Freedberg KA. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41 1316–23.
| Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Crossref | GoogleScholarGoogle Scholar | 16206108PubMed |
[7] Kuritzkes DR. HIV resistance: frequency, testing, mechanisms. Top HIV Med 2007; 15 150–4.
| 18073450PubMed |
[8] Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, Harmen S, Wood M, Sandstrom P. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV Strain and Drug Resistance Surveillance Program. J Acquir Immune Defic Syndr 2006; 42 86–90.
| A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV Strain and Drug Resistance Surveillance Program.Crossref | GoogleScholarGoogle Scholar | 16763495PubMed |
[9] Vercauteren J, Wensing AMJ, van de Vijver DAMC, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit J-C, Åsjö B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer- , Stöck E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme A-M, Boucher CAB. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200 1503–8.
| Transmission of drug-resistant HIV-1 is stabilizing in Europe.Crossref | GoogleScholarGoogle Scholar | 19835478PubMed |
[10] Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma G, Douglas JM. Jr,. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma G, Douglas JM. Jr,. The epidemiology of antiretroviral drug resistance among drug-naive HIV-l-infected persons in 10 US cities. J Infect Dis 2004; 189 2174–80.
| The epidemiology of antiretroviral drug resistance among drug-naive HIV-l-infected persons in 10 US cities.Crossref | GoogleScholarGoogle Scholar | 15181563PubMed |
[11] UK Group on Transmitted HIV Drug Resistance Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331 1368–74.
| Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.Crossref | GoogleScholarGoogle Scholar | 16299012PubMed |
[12] Wensing AMJ, van de Vijver DA, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix Me-L , Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, Mendoza C, Meyer L, Nielsen C, Op de Coul E, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit J-C, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme A-M, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher C. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192 958–66.
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.Crossref | GoogleScholarGoogle Scholar |
[13] Kleyn TJ, Liedtke MD, Harrison DL, Lockhart SM, Salvaggio MR, Ripley TL, Rathbun RC. Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic. Ann Pharmacother 2014; 48 470–5.
| Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic.Crossref | GoogleScholarGoogle Scholar | 24473489PubMed |
[14] Snedecor SJ, Sudharshan L, Nedrow K, Abhijeet B, Simpson KN, Haider S, Chambers R, Craig C, Stephens J. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res Hum Retroviruses 2014; 30 753–68.
| Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXht1Kjur3N&md5=f60f1ae563a655e27adf169a5a967a53CAS | 24925216PubMed |
